201 related articles for article (PubMed ID: 29858023)
1. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Mertsoylu H; Hahn SM
Lung Cancer; 2018 Jul; 121():30-36. PubMed ID: 29858023
[TBL] [Abstract][Full Text] [Related]
2. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
[TBL] [Abstract][Full Text] [Related]
3. Baseline hemoglobin <11.0 g/dL has stronger prognostic value than anemia status in nasopharynx cancers treated with chemoradiotherapy.
Topkan E; Ekici NY; Ozdemir Y; Besen AA; Yildirim BA; Mertsoylu H; Sezen D; Selek U
Int J Biol Markers; 2019 Jun; 34(2):139-147. PubMed ID: 30864463
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Besen AA; Findikcioglu A; Ozyilkan O
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1123-1132. PubMed ID: 29887509
[TBL] [Abstract][Full Text] [Related]
5. Definitive concurrent chemoradiotherapy outcomes in Stage IIIB nonsmall cell lung cancer patients younger than 45 years: A retrospective analysis of 145 patients.
Topkan E; Guler OC; Ozdemir Y
J Cancer Res Ther; 2020; 16(4):757-763. PubMed ID: 32930115
[TBL] [Abstract][Full Text] [Related]
6. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
Topkan E; Ozdemir Y; Kucuk A; Besen AA; Mertsoylu H; Sezer A; Selek U
PLoS One; 2019; 14(7):e0218627. PubMed ID: 31329602
[TBL] [Abstract][Full Text] [Related]
7. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
Gielda BT; Mehta P; Khan A; Marsh JC; Zusag TW; Warren WH; Fidler MJ; Abrams RA; Bonomi P; Liptay M; Faber LP
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):985-91. PubMed ID: 20932684
[TBL] [Abstract][Full Text] [Related]
8. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
[TBL] [Abstract][Full Text] [Related]
10. Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
Topkan E; Parlak C; Selek U
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):697-704. PubMed ID: 24035331
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
12. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
13. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
14. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
15. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy.
Holgersson G; Bergstrom S; Hallqvist A; Liv P; Nilsson J; Willen L; Nyman J; Ekman S; Henriksson R; Bergqvist M
Neoplasma; 2017; 64(6):909-915. PubMed ID: 28895417
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa.
Debus J; Drings P; Baurecht W; Angermund R
Radiother Oncol; 2014 Jul; 112(1):23-9. PubMed ID: 25129551
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study.
Lavey RS; Liu PY; Greer BE; Robinson WR; Chang PC; Wynn RB; Conrad ME; Jiang C; Markman M; Alberts DS
Gynecol Oncol; 2004 Oct; 95(1):145-51. PubMed ID: 15385124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
